

November 10, 2020

**The General Manager**  
**Department of Corporate Services - CRD**  
**Bombay Stock Exchange Limited**  
**Phiroze Jeejeebhoy Towers**  
**Dalal Street**  
**Mumbai 400 001**

Dear Sir,

**Subject: Outcome of Board Meeting.**

This is with reference to our letter dated 03<sup>rd</sup> November 2020.

At the meeting of the Board of Directors of the company held on 10<sup>th</sup> November 2020, following actions have taken place:

- 1) Approved the Unaudited Standalone and Consolidated Financial Results alongwith Limited Review Report of the Company for the quarter and Half Year ended on 30<sup>th</sup> September 2020.
- 2) Approved change of registered office address from Plot No: 68, 69, 70, 70A, IDA Anrich Industrial Area, Bollaram, Medak Dist – 502325 Telangana India to Plot No: 69 & 70 IDA Bollaram, Sangareddy District – 502325, Telangana, India.
- 3) The Board has approved to transfer TrabiORAL technology into its wholly owned subsidiary on terms and conditions approved by the Board of Directors of Transgene Biotek Ltd and its subsidiary Peroral Bio Pvt Ltd.

This is for your information and records.

Thanking you

Yours Sincerely  
For **TRANSGENE BIOTEK LIMITED**



**DR. K. KOTESWARA RAO**  
**CHAIRMAN & MANAGING DIRECTOR**  
**DIN: 02287235**



**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020**

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Audited)	30.09.2020 (UnAudited)	30-09-2019 (Audited)	31.03.2020 (Audited)
							35,754
1	Revenue from operations	-	-	-	8,76,940	9,47,634	17,88,820
2	Other income (net)	4,38,470	4,38,470	5,09,164	8,76,940	9,47,634	18,24,574
3	<b>Total income (1 + 2)</b>	<b>4,38,470</b>	<b>4,38,470</b>	<b>5,09,164</b>	<b>8,76,940</b>	<b>9,47,634</b>	
4	<b>EXPENSES</b>						
	Cost of materials consumed	95,267	42,078	6,590	1,37,345	4,08,099	1,47,876
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-	-	-
	Employee benefits expense	7,51,572	7,32,873	7,07,850	14,84,445	14,66,788	28,95,496
	Finance costs	6,65,681	6,65,681	7,51,534	13,31,362	23,02,326	38,05,393
	Depreciation and amortisation expense	247,42,519	247,42,519	247,42,286	494,85,038	494,84,572	989,69,145
	Other expenses	9,18,266	6,24,383	16,27,207	15,42,649	24,25,246	56,29,036
	<b>Total expenses</b>	<b>271,73,305</b>	<b>268,07,534</b>	<b>278,35,467</b>	<b>539,80,839</b>	<b>560,87,031</b>	<b>1114,46,946</b>
5	<b>Profit before exceptional items, share of profit from associate &amp; joint venture and tax (3 - 4)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
6	Exceptional item (net)	-	-	-	-	-	-
7	<b>Profit before tax (5 - 6)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
8	<b>Tax expense</b>						
	Tax adjustments for earlier years	-	-	-	-	-	-
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
	<b>Total tax expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
9	<b>Profit for the year (7 - 8)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
10	<b>Other comprehensive income</b>						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
11	<b>Total comprehensive income for the year (9 + 10)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
12	<b>Earnings per equity share</b>						
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.35)	(0.35)	(0.36)	(0.70)	(0.73)	(1.45)
	Diluted (Rs.)	(0.35)	(0.35)	(0.36)	(0.70)	(0.73)	(1.45)

Notes:

1. **TrabiORAL:**

- (a) In-vivo studies on different molecules delivered on TrabiORAL platform held up for several months due to Covid effect have been completed during Q2 and results of those studies provided exciting results.  
(b) With solid data proving the efficacy and because of its wide-ranging applications, the management has initiated an elaborate plan to provide an unhindered progress to attract global pharma companies extracting inherent value of TrabiORAL.  
(c) In line with its planned monetization process, several global pharma majors have been lined up to demonstrate the utility and versatility of

2. With intense competition on Covid vaccine front, the management has dropped its plans to enter this space.  
3. Since much progress could not be achieved because of Covid lockdown effecting globally, a request for extension of one more year for recovery of GDR funds has been approved by SEBI.  
4. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.  
5. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 10<sup>th</sup> November 2020.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao  
Chairman & Managing Director



Date: 10-11-2020  
Place: Hyderabad

**TRANSGENE BIOTEK LIMITED**  
69 & 70, IDA, Bollaram, Sangareddy District - 502325, Telangana  
CIN NO: L85195TG1990PLC011065

**Standalone Statement of assets and liabilities**

Particulars	As at September 30, 2020	As at March 31, 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	211,14,014	220,57,361
Capital Work in Progress	-	-
Other intangible assets	2414,41,437	2899,63,539
Intangible assets under development	186,76,633	186,76,633
<b>Financial assets</b>		
(a) Investments	-	-
(b) Loans	2302,04,250	2302,04,250
Other non-current assets	11,12,923	9,78,749
<b>Total Non - Current Assets</b>	<b>5125,49,257</b>	<b>5618,80,532</b>
<b>Current Assets</b>		
Inventories	3,84,312	3,84,312
<b>Financial assets</b>		
(a) Cash and cash equivalents	2,92,437	3,89,905
Current Tax Assets	-	-
Other current assets	59,95,766	59,59,461
<b>Total Current assets</b>	<b>66,72,515</b>	<b>67,33,678</b>
<b>Total Assets</b>	<b>5192,21,772</b>	<b>5686,14,210</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	7577,00,000	7577,00,000
Other equity	(6598,34,405)	(6067,30,506)
Equity attributable to owners of the Company	978,65,595	1509,69,494
<b>Total Equity</b>	<b>978,65,595</b>	<b>1509,69,494</b>
<b>Non-current liabilities</b>		
<b>Financial Liabilities</b>		
(a) Borrowings	440,90,807	427,59,445
Provisions	2302,04,250	2302,04,250
Other non-current liabilities	78,92,463	87,69,403
<b>Total Non-current liabilities</b>	<b>2821,87,520</b>	<b>2817,33,098</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(a) Borrowings	644,78,149	605,08,298
(b) Trade payables	33,15,530	37,95,952
Provisions	699,27,110	699,01,787
Other current liabilities	14,47,868	17,05,582
<b>Total Current liabilities</b>	<b>1391,68,657</b>	<b>1359,11,619</b>
<b>Total liabilities</b>		
<b>Total Equity and liabilities</b>	<b>5192,21,772</b>	<b>5686,14,210</b>

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao  
Chairman & Managing Director



Date:10-11-2020  
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements

Other operating expenses

Particulars	For the Period ended Sept 30,2020
Power and fuel	48,700
Legal and Professional Charges	6,55,160
Annual Custody and issuer fee	-
Telephone Expenses	10,198
Municipality Tax	-
Patents Application fee	92,000
Independent Directros empannelment Fee	-
Interest and penalties	-
Testing Charges	-
ROC filing charges	300
Google drive	390
Conveyance	2,421
Bank charges	9
Advertisement Exp	15,085
Miscllaneous Expenses	1
Postage & Courier	8,432
Directros Sitting fee	45,000
Repairs and Maintenance	3,000
AGM VC Charges	7,500
Pollution Control	2,070
Printing & Stationary	12,500
ROC challan	3,500
Transport Charges	2,000
Website Service	10,000
<b>Total</b>	<b>9,18,266</b>



*[Handwritten signature]*

**TRANSGENE BIOTEK LIMITED**

69 & 70, IDA, Bollaram, Sangareddy DISTRICT.

Standalone Unaudited Statement of Cash Flows for the half year ended September 30, 2020

Particulars	For the Half year ended September,2020 (Un Audited)		For the Half year ended September,2019 (Audited)	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Profit before tax		(531,03,899)		(551,39,397)
<u>Adjustments for:</u>				
Depreciation and amortisation expense	494,85,038		494,84,578	
Finance costs	13,31,362		23,02,326	
Amortisation of government grant	(8,76,940)		(8,76,940)	
Supplier Advances Written off	-		-	
Liabilities / provisions no longer required written back	-		-	
Bad debts written off	-		-	
Non Cash Income	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(31,64,439)		(42,29,433)
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables	-		-	
Other Current assets	(36,305)		(1,06,910)	
Inventories	-		-	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(4,80,422)		2,07,881	
Provision (CL)	25,323		80,489	
Borrowing (CL)	39,69,852		59,83,577	
Other current liabilities	(2,57,714)		(2,23,653)	
Cash generated from operations		56,295		17,11,951
Net income tax paid		-		-
<b>Net cash flow from operating activities (A)</b>		<b>56,295</b>		<b>17,11,951</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on fixed assets, including capital advances	(19,589)		-	
Sale of Assets	-		-	
Interest Received	-		-	
Loan to other parties	-		-	
Non Current Assets	(1,34,174)		(3,96,926)	
<b>Net cash (used in) / flow from investing activities (B)</b>		<b>(1,53,763)</b>		<b>(3,96,926)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from issue of equity shares	-		-	
Finance costs	-		-	
Proceeds from Borrowings	-		(20,00,000)	
Payment of Borrowing	-		-	
<b>Net cash flow (used in) financing activities (C)</b>		<b>-</b>		<b>(20,00,000)</b>
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(97,468)</b>		<b>(6,84,975)</b>
Cash and cash equivalents at the beginning of the year		3,89,905		9,96,303
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
<b>Cash and cash equivalents at the end of the year</b>		<b>2,92,437</b>		<b>9,26,861</b>

For TRANSGENE BIOTEK LIMITED

  
Dr.K.Koteswara Rao  
Managing Director



Date: 10-11-2020  
Place: Hyderabad



**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020**

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Audited)	30.09.2020 (UnAudited)	30-09-2019 (Audited)	31.03.2020 (Audited)
1	Revenue from operations	-	-	-	-	-	35,754
2	Other income (net)	4,38,470	4,38,470	5,09,164	8,76,940	9,47,634	17,88,820
3	<b>Total income (1 + 2)</b>	<b>4,38,470</b>	<b>4,38,470</b>	<b>5,09,164</b>	<b>8,76,940</b>	<b>9,47,634</b>	<b>18,24,574</b>
4	<b>EXPENSES</b>						
	Cost of materials consumed	95,267	42,078	6,590	1,37,345	4,08,099	1,47,876
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-	-	-
	Employee benefits expense	7,51,572	7,32,873	7,07,850	14,84,445	14,66,788	28,95,496
	Finance costs	6,65,681	6,65,681	7,51,534	13,31,362	23,02,326	38,05,393
	Depreciation and amortisation expense	247,42,519	247,42,519	247,42,286	494,85,038	494,84,572	989,69,145
	Other expenses	9,18,266	6,24,383	16,27,207	15,42,649	24,25,246	56,29,036
	<b>Total expenses</b>	<b>271,73,305</b>	<b>268,07,534</b>	<b>278,35,467</b>	<b>539,80,839</b>	<b>560,87,031</b>	<b>1114,46,946</b>
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(267,34,835)	(263,69,064)	(273,26,303)	(531,03,899)	(551,39,397)	(1096,22,372)
6	Exceptional item (net)	-	-	-	-	-	-
7	<b>Profit before tax (5 - 6)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
8	<b>Tax expense</b>						
	Tax adjustments for earlier years	-	-	-	-	-	-
	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	-
	<b>Total tax expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
9	<b>Profit for the year (7 - 8)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
10	<b>Other comprehensive income</b>						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	-	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
11	<b>Total comprehensive income for the year (9 + 10)</b>	<b>(267,34,835)</b>	<b>(263,69,064)</b>	<b>(273,26,303)</b>	<b>(531,03,899)</b>	<b>(551,39,397)</b>	<b>(1096,22,372)</b>
12	<b>Earnings per equity share</b>						
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.35)	(0.35)	(0.36)	(0.70)	(0.73)	(1.45)
	Diluted (Rs.)	(0.35)	(0.35)	(0.36)	(0.70)	(0.73)	(1.45)

**Notes:**

**1. TrabiORAL:**

- (a) In-vivo studies on different molecules delivered on TrabiORAL platform held up for several months due to Covid effect have been completed during Q2 and results of those studies provided exciting results.
  - (b) With solid data proving the efficacy and because of its wide-ranging applications, the management has initiated an elaborate plan to provide an unhindered progress to attract global pharma companies extracting inherent value of TrabiORAL
  - (c) In line with its planned monetization process, several global pharma majors have been lined up to demonstrate the utility and versatility of TrabiORAL platform.
2. With intense competition on Covid vaccine front, the management has dropped its plans to enter this space.
  3. Since much progress could not be achieved because of Covid lockdown effecting globally, a request for extension of one more year for recovery of GDR funds has been approved by SEBI.
  4. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.
  5. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 10<sup>th</sup> November 2020.

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao  
 Chairman & Managing Director



Date: 10-11-2020  
 Place: Hyderabad

**Consolidated Statement of assets and liabilities**

Particulars	As at September 30, 2020	As at March 31, 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	211,14,014	220,57,361
Capital Work in Progress	-	-
Other intangible assets	2414,41,437	2899,63,539
Intangible assets under development	186,76,633	186,76,633
Financial assets		
(a) Investments		
(b) Loans	13290,24,004	13290,24,004
Other non-current assets	11,12,923	9,78,749
<b>Total Non - Current Assets</b>	<b>16113,69,011</b>	<b>16607,00,286</b>
<b>Current Assets</b>		
Inventories	3,84,312	3,84,312
Financial assets		
(a) Trade receivables	84,460	84,460
(b) Cash and cash equivalents	2,92,437	3,89,905
Current Tax Assets	-	-
Other current assets	59,95,766	59,59,461
<b>Total Current assets</b>	<b>67,56,975</b>	<b>68,18,138</b>
<b>Total Assets</b>	<b>16181,25,985</b>	<b>16675,18,424</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	7577,00,000	7577,00,000
Other equity	(4840,66,231)	(4309,62,332)
Equity attributable to owners of the Company	2736,33,769	3267,37,668
<b>Total Equity</b>	<b>2736,33,769</b>	<b>3267,37,668</b>
<b>Non-current liabilities</b>		
<b>Financial Liabilities</b>		
(a) Borrowings	440,90,807	427,59,445
Provisions	11522,13,978	11522,13,978
Other non-current liabilities	78,92,463	87,69,403
<b>Total Non-current liabilities</b>	<b>12041,97,248</b>	<b>12037,42,826</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(a) Borrowings	644,78,149	605,08,298
(b) Trade payables	33,15,530	37,95,952
© Other Financial Liabilities	11,26,311	11,26,311
Provisions	699,27,110	699,01,787
Other current liabilities	14,47,868	17,05,582
<b>Total Current liabilities</b>	<b>1402,94,968</b>	<b>1370,37,930</b>
<b>Total liabilities</b>		
<b>Total Equity and liabilities</b>	<b>16181,25,985</b>	<b>16675,18,424</b>

For TRANSGENE BIOTEK LIMITED



Dr. K. Koteswara Rao  
Chairman & Managing Director

Date: 10-11-2020  
Place: Hyderabad



**TRANSGENE BIOTEK LIMITED**

69 & 70, IDA, Bollaram, Sangareddy DISTRICT.

Consolidated Unaudited Statement of Cash Flows for the half year ended September 30, 2020

Particulars	For the Half year ended September, 2020 (Un Audited)		For the Half year ended September, 2019 (Audited)	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Profit before tax		(531,03,899)		(551,39,397)
<u>Adjustments for:</u>				
Depreciation and amortisation expense	494,85,038		494,84,578	
Finance costs	13,31,362		23,02,326	
Amortisation of government grant	(8,76,940)		(8,76,940)	
Supplier Advances Written off	-		-	
Liabilities / provisions no longer required written back	-		-	
Bad debts written off	-		-	
Non Cash Income	-		-	
Other Non cash Expenses	-		-	
<b>Operating profit before working capital changes</b>		<b>(31,64,439)</b>		<b>(42,29,433)</b>
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables	-		-	
Other Current assets	(36,305)		(1,06,910)	
Inventories	-		-	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(4,80,422)		2,07,881	
Provision (CL)	25,323		80,489	
Borrowing (CL)	39,69,852		59,83,577	
Other current liabilities	(2,57,714)		(2,23,653)	
<b>Cash generated from operations</b>		<b>56,295</b>		<b>17,11,951</b>
Net income tax paid		-		-
<b>Net cash flow from operating activities (A)</b>		<b>56,295</b>		<b>17,11,951</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on fixed assets, including capital advances	(19,589)		-	
Sale of Assets	-		-	
Interest Received	-		-	
Loan to other parties	-		-	
Non Current Assets	(1,34,174)		(3,96,926)	
<b>Net cash (used in) / flow from investing activities (B)</b>		<b>(1,53,763)</b>		<b>(3,96,926)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from issue of equity shares	-		-	
Finance costs	-		-	
Proceeds from Borrowings	-		-	
Payment of Borrowing	-		(20,00,000)	
<b>Net cash flow (used in) financing activities (C)</b>		<b>-</b>		<b>(20,00,000)</b>
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(97,468)</b>		<b>(6,84,975)</b>
Cash and cash equivalents at the beginning of the year		3,89,905		9,96,303
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
<b>Cash and cash equivalents at the end of the year</b>		<b>2,92,437</b>		<b>9,26,861</b>

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao  
Chairman & Managing Director



Date: 10-11-2020

Place: Hyderabad





### Limited Review Report

To,

The Board of directors

M/s. Transgene Biotek Limited

Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 September 2020 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities

**Name of the entity Relationship**

- |                                |            |
|--------------------------------|------------|
| 1. Transgene Biotek HK Limited | Subsidiary |
|--------------------------------|------------|



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed ,or that it contains any material misstatement.
6. We did not review the interim financial results of one subsidiary included in the Statement ,whose interim financial results reflect total revenues of Rs. 0million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 September 2020, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates  
Chartered Accountants  
FRNo.010114S

  
Manisha Dubey  
Proprietor  
M No.212664  
Place: Hyderabad  
Date: 10.11.2020



**Unique Document Identification Number (UDIN) for this document is  
20212664AAAADS3715**



**Limited review report**

To,

The Board of directors

M/s. Transgene Biotek Limited


Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 30 September 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates

Chartered Accountants

FRNo.010114S

  
Manisha Dubey

Proprietor

M No.212664

Place: Hyderabad

Date: 10.11.2020

